FILING ANALYSIS · WEDNESDAY, NOVEMBER 18

Retension Pharmaceuticals, Inc. RTSN — 8-K: Results of Operations and Financial Condition

negative

The company's recent IPO generated $51.75 million in gross proceeds, which will be used to complete the Phase 2b clinical trial of RTN-001 and prepare for Phase 3, but the filing also shows a significant decrease in cash position from $18.9 million to $9.2 million as of September 30, 2026, before the IPO proceeds

The filing

8-K - Retension Pharmaceuticals, Inc. (0002002988) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+